Project Grant R01AI183430

Award Date 6/14/24
Completion Date 5/31/29
Dollars Obligated $2.6M
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
New Haven, CT 06519, USA
Similar Awards
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $681,278 to The Johns Hopkins University to conduct research on the HIV latent reservoir and the mechanisms driving clonal proliferation and persistence of infected cells in people living with HIV on antiretroviral therapy. The key objectives are to: 1) Fully characterize the intact and defective provirus clonality...
This federal Project Grant award of $1,766,954.46 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to investigate the immune microenvironments that impact HIV persistence and expression during antiretroviral therapy (ART). The key objectives are to: 1) Determine the location, phenotype, and microenvironment of HIV viral RNA (vRNA)-expressing cells in secondary lymphoid tissues of...
This federal Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $884,322 to support research into the mechanisms that create and sustain the HIV reservoir - a population of latently infected cells that persists during suppressive antiretroviral therapy and prevents a cure for HIV. The research team, led by Dr. Reeves and collaborators at the Fred Hutchinson Cancer...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $882,149 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Oregon Health & Science University (OHSU) to study the persistence and functionality of HIV-specific CD8+ T cell responses in early treated children compared to adults after long-term antiretroviral therapy (ART). The key objectives of this 2-year project are to: 1) Determine the magnitude, phenotype, and...
This federal Project Grant award, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to elucidate the molecular mechanisms underlying T cell dysfunction and HIV persistence in persons with HIV (PWH). The $500,000 award, effective from September 1, 2024 to August 31, 2029, will support research conducted by The General Hospital Corporation (Massachusetts General Hospital) to identify and...
This Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop a novel HIV cure strategy by targeting CD127-expressing tissue reservoir cells. The total funding amount is $250,791.00, with an award date of August 6, 2024 and an ultimate completion date of July 31, 2026. The key products and services to be delivered under this grant include: Utilizing an ex vivo...
This Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), is focused on investigating the role of RNA modifications in driving chronic inflammation in people living with HIV (PLWH) who are on antiretroviral therapy (ART). The primary awardee, Trustees of Boston University, will receive $854,360 over the 5-year award period to identify the molecular mechanisms linking specific RNA...
This $1,010,290 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) will fund research at Emory University to investigate the role of alveolar macrophages as potential HIV reservoirs and drivers of residual inflammation and immune activation in people living with HIV (PLWH) on antiretroviral therapy. The study aims to: 1) Determine the contribution of alveolar macrophages as reservoirs...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $211,950 in funding to the University of California, Irvine. The award period is from August 1, 2024 to June 30, 2026. The primary objective of this research project is to investigate whether immune complexes consisting of HIV-1 Gag protein, viral RNA, and anti-Gag antibodies drive the persistent immune activation...
This $499,550 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research into understanding and controlling the latent HIV reservoir in memory CD4+ T cells. The key objectives are to investigate how the BACH2 transcription factor regulates the terminal differentiation of CCR5+ CD4+ T cells, which are the primary targets for HIV infection and reservoir establishment. The...

UNDERSTANDING HIV-1 PERSISTENCE AND HIV-1-INDUCED INFLAMMATION IN TISSUES - PROJECT SUMMARY DESPITE EFFECTIVE ANTIRETROVIRAL THERAPY (ART), HIV RESIDES IN INFECTED CELLS AS INTEGRATED PROVIRUSES AND PERSISTS LIFELONG. WHILE ART SUPPRESSES PLASMA VIRAL LOAD TO CLINICALLY UNDETECTABLE LEVELS, ART DOES NOT KILL THE EXISTING HIV-INFECTED CELLS. HIV-INDUCED CHRONIC IMMUNE ACTIVATION ACCELERATES AGING, INCREASES RISKS OF PREMATURE CARDIOVASCULAR DISEASES, AND INCREASES CANCER RISKS. IT WAS BELIEVED THAT HIV LATENTLY INFECTED CELLS, AS OPPOSED TO TRANSCRIPTIONALLY ACTIVE HIV-INFECTED CELLS, ARE THE MAJOR BARRIER TO CURE. TRANSCRIPTIONALLY ACTIVE HIV-INFECTED CELLS SHOULD PRESUMABLY DIE OF VIRAL CYTOPATHIC EFFECTS OR IMMUNE CLEARANCE AND THEREFORE WERE NOT THE MAJOR FOCUS OF RESEARCH. HOWEVER, RECENT STUDIES REVEALED THAT TRANSCRIPTIONALLY ACTIVE HIV-INFECTED CELLS CAN SURVIVE VIRAL CYTOPATHIC EFFECT, ESCAPE IMMUNE CLEARANCE, PERSIST, AND PROLIFERATE DESPITE SUPPRESSIVE ART. THIS IS BECAUSE ALTHOUGH ART INHIBITS VIRAL ENZYME FUNCTION, ART DOES NOT INHIBIT HIV LTR PROMOTER ACTIVITY. DESPITE SUPPRESSIVE ART, HIV LTR PROMOTER FIRES BURSTS OF VIRAL PROTEIN EXPRESSION IN PEOPLE LIVING WITH HIV UNDER SUPPRESSIVE ART AND INDUCE IMMUNE ACTIVATION. OUR CENTRAL HYPOTHESIS IS THAT TRANSCRIPTIONALLY ACTIVE HIV- INFECTED CD4+ T CELLS DRIVE CHRONIC IMMUNE ACTIVATION IN TISSUES. OUR GOAL IS TO EXAMINE HIV-INDUCED IMMUNE ACTIVATION AT THE SINGLE-CELL LEVEL. IDENTIFYING HIV-INFECTED CELLS FOR MECHANISTIC UNDERSTANDING IS EXTREMELY CHALLENGING BECAUSE OF THE RARITY AND HETEROGENEITY OF HIV-INFECTED CELLS. FIRST, ONLY 1 IN A MILLION CD4+ T CELLS HARBOR INFECTIOUS HIV PROVIRUS, WHILE AROUND 1000 PER MILLION CD4+ T CELLS HARBOR DEFECTIVE HIV PROVIRUS. THE REMAINING 99.9% OF CD4+ T CELLS ARE UNINFECTED. THEREFORE, BULK TRANSCRIPTOMIC APPROACHES MEASURE THE 99.9% OF UNINFECTED CELLS AND DO NOT REFLECT THE CELLULAR STATES OF HIV-INFECTED CELLS. SECOND, CD4+ T CELLS ARE EXTREMELY HETEROGENEOUS BECAUSE OF DISTINCT T CELL DIFFERENTIATION (SUCH AS NAIVE, CENTRAL MEMORY, AND EFFECTOR MEMORY), POLARIZATION (SUCH AS TH1, TH1, TH17, TFH, TREG), IMMUNE PROGRAMS (SUCH AS ACTIVATION, EXHAUSTION, AND CYTOKINE RESPONSES). THEREFORE, SINGLE-CELL MULTI-OMIC PROFILING IS NEEDED TO IDENTIFY THE RARE AND HETEROGENEOUS HIV-INFECTED CELLS. THIRD, THERE IS NO CELLULAR MARKERS THAT CAN SPECIFICALLY DISTINGUISH HIV-INFECTED CELLS FROM UNINFECTED CELLS. THEREFORE, UNDERSTANDING HIV PERSISTENCE IN VIVO HAS BEEN A MAJOR BARRIER IN THE FIELD. TO RESOLVE THE RARITY AND HETEROGENEITY OF HIV RESERVOIR, OUR APPROACH IS TO USE SINGLE-CELL MULTIOMIC APPROACHES TO PROFILE THE RARE HIV-INFECTED CELLS AT THE SINGLE CELL LEVEL AND EXAMINE THE HETEROGENEOUS INFECTED CELLS. WE PIONEERED SINGLECELL MULTI-OMIC PROFILING TO ADVANCE OUR UNDERSTANDING OF HIV RESERVOIR. USING SINGLE-CELL ECCITESEQ, WE USED HIV RNA EXPRESSION AS A SURROGATE TO IDENTIFY TRANSCRIPTIONALLY ACTIVE HIV-INFECTED CELLS AND THEIR SINGLE- CELL TRANSCRIPTOME LANDSCAPE. USING SINGLE-CELL DOGMASEQ, WE IDENTIFIED LATENT (HIV DNA+ RNA-) AND TRANSCRIPTIONALLY ACTIVE (HIV RNA+) HIV-INFECTED CELLS AND THEIR EPIGENETIC REGULATORS, TRANSCRIPTIONAL LANDSCAPE, AND SURFACE PROTEIN EXPRESSION. IN AIM 1, WE WILL EXAMINE THE IMMUNE ACTIVATION PROGRAMS IN HIV-INFECTED CELLS. IN AIM 2, WE WILL EXAMINE WHETHER HIV INFECTION INDUCES IMMUNE ACTIVATION IN UNINFECTED IMMUNE CELLS.

Posted 6/14/24, 12:00 AM